BioCentury
ARTICLE | Company News

Replidyne infectious news

September 1, 2008 7:00 AM UTC

Replidyne restructured and reduced headcount across all areas by 19 (80%) to 5. The company also suspended development of its sole remaining compound, REP3123, a preclinical methionyl tRNA synthetase...